TG Therapeutics Reports Q4 Earnings

Biopharmaceutical company posts $23 million in Q4 profit but falls short of Wall Street expectations

Published on Feb. 26, 2026

Got story updates? Submit your updates here. ›

TG Therapeutics Inc., a biopharmaceutical company based in Morrisville, North Carolina, reported fourth-quarter profit of $23 million. However, the results fell short of Wall Street expectations, with the company posting earnings of 14 cents per share compared to the average estimate of 35 cents per share from five analysts surveyed by Zacks Investment Research.

Why it matters

TG Therapeutics is a key player in the biopharmaceutical industry, and its quarterly earnings reports are closely watched by investors and analysts to gauge the company's financial health and performance. The miss on Wall Street expectations could impact the company's stock price and investor confidence.

The details

For the full year, TG Therapeutics reported a profit of $447.2 million, or $2.77 per share, on revenue of $616.3 million. In the fourth quarter, the company posted revenue of $192.6 million.

  • TG Therapeutics reported its fourth-quarter earnings on Thursday, February 26, 2026.

The players

TG Therapeutics Inc.

A biopharmaceutical company based in Morrisville, North Carolina that develops therapies for B-cell malignancies and autoimmune diseases.

Got photos? Submit your photos here. ›

The takeaway

TG Therapeutics' fourth-quarter earnings miss highlights the challenges the biopharmaceutical industry faces in meeting Wall Street expectations, even as the company reported strong full-year results. Investors will be closely watching the company's future performance and developments in its drug pipeline.